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Background: Pressure ulcers are common among older adults, but knowledge about 
nutritional risk factors is still developing. Vitamin D deficiency is common in the elderly 
population and is required for normal skin proliferation. The role of vitamin D in pressure 
ulceration and wound healing is not known. The purpose of this case–control study was 
to determine the association between vitamin D levels and pressure ulceration in an older 
community-dwelling cohort.
Methods: All cases and controls were community-dwelling elderly older than 60 years in 
a primary care panel in Olmsted County, MN. Pressure ulcer cases were defined clinically. 
The controls were age-matched and gender-matched to controls without pressure ulceration. 
The main exposure variable was 25-hydroxyvitamin D levels in both groups. The other expo-
sure variable was the Charlson Comorbidity Index used to measure medical comorbidity. 
The   analysis included univariate and conditional logistic regression for 25-hydroxyvitamin D 
levels.
Results: The average (standard deviation) age of the study participants with a pressure ulcer was 
80.46 years (±8.67), and the average vitamin D level was 30.92 ng/mL (±12.46). In univariate 
analysis, Vitamin D deficiency (levels , 25 ng/mL) was associated with pressure ulcers 
(odds ratio: 1.871, P = 0.0154). Comorbidities of the subjects calculated using the Charlson 
Comorbidity Index were also associated with pressure ulcers (odds ratio: 1.136, P , 0.001). 
In the final conditional logistical regression model, the association of Vitamin D and pressure 
ulcers became nonsignificant after adjustment for comorbid illness.
Conclusion: Medical comorbidities increased the risk of pressure ulceration. Vitamin D 
deficiency was not an independent risk factor for pressure ulceration, and may be a marker of 
comorbid illness.
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Introduction
Pressure ulcers represent a common condition seen most often in high-risk populations, 
such as older patients and those with physical impairment. The epidemiology of 
pressure ulcers varies considerably by clinical setting, with incidence rates ranging from 
0.4% to 38% in acute care, 2.2% to 23.9% in long-term care, and 0% to 17% in home 
care.1 In acute care facilities in the US alone, an estimated 2.5 million pressure ulcers 
are treated each year.2 Pressure ulcers cause morbidity and significant suffering, so there 
is a strong impetus for action. The development of pressure ulcers after hospitalization 
can interfere with functional recovery, and may be complicated by pain and infection. 
Pressure ulcers can contribute to an increased length of hospital stay.3 The presence of 
pressure ulcers is a marker of poor overall prognosis and may contribute to premature Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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mortality in some patients.4,5 Thus, there is a clear need to 
understand some of the risk factors for pressure ulceration.
Vitamin D is a fat-soluble nutrient that humans obtain 
via the diet and by synthesis in the skin upon exposure to 
ultraviolet B light. The vitamin D receptor was discovered 
in the mid 1970s.6,7 Its presence in a number of body 
tissues not previously associated with calcium and 
phosphorus metabolism was discovered by immunochemical 
measurements and by the accumulation of titrated 1,25-
dihydroxyvitamin D3 in target nuclei.8
Skin is a target of vitamin D action. This has been 
clearly established by the presence of the vitamin D 
receptors in keratinocytes, sebocytes, and dermal papilla 
cells.9–11 Vitamin D has been associated with proliferation, 
differentiation, and immunoregulation of cells. Vitamin D is 
shown to play a role in terminal differentiation of epider-
mal cells in vitro.12 Vitamin D has some potential role in 
skin health and maintenance, and hence the interest in the 
relationship between vitamin D and pressure ulcers. All the 
aforementioned studies have focused on wound healing. 
Unfortunately, there is no evidence in the literature looking 
specifically at vitamin D and development or healing of 
pressure ulcers. The association between vitamin D and 
pressure ulceration is not known. We suspect that there may 
be a relationship between vitamin D levels and development 
of  pressure ulcers. The objective of this age-matched and 
gender-matched case–control study was to determine the 
association between vitamin D levels and the development 
of pressure ulcers.
Methods
study design
This was a matched case–control study involving adult 
outpatients at the Division of Primary Care Internal Medicine, 
Mayo Clinic, Rochester, MN. This was a nested case–control 
study of a cohort of individuals with documented vitamin D 
levels. The Mayo Clinic institutional review board reviewed 
and approved the protocol. The authors conducted all 
aspects of the research in this project in accordance with the 
principles of the Declaration of Helsinki.13
setting
Mayo is an academic medical center with both faculty 
physicians and training health care providers. Primary Care 
Internal Medicine provides primary care to the local residents 
of Rochester and Olmsted County. Olmsted County had a 
population of 143,962 in 2009, with 89% being White, 4% 
Black/African-American, 0.3% American Indian or Alaska 
native, 5.4% Asian, and 3.1% Hispanic/Latino.14 The study 
period covered March 2001 to December 2010.
Participants
Participants were adults older than 60 years who were 
assigned to a Primary Care Internal Medicine care provider 
during the study period. All the participants were community-
dwelling or lived in an assisted living facility within Olmsted 
County. Residents living within a skilled nursing facility 
or who did not provide consent for medical record review 
were excluded.
Cases were subjects who were diagnosed with pressure 
ulcers from March 2001 through December 2010 and had a 
vitamin D level available prior to the event. These cases were 
drawn from a previous cohort of individuals with documented 
vitamin D levels. Controls were selected from the same cohort 
who had their vitamin D level available and were matched 
for age and gender. The diagnosis of pressure ulceration was 
made clinically by medical providers and was documented in 
the medical records and/or billed as a pressure ulcer. Patients 
were matched for both gender and for age ± 4 years. There 
was 1:2 matching of cases to controls.
Bias within the study was minimized by including all 
cases of pressure ulceration with vitamin D levels within the 
cohort. Matching for age and gender allowed the investigators 
to reduce the potential effects of these two likely confounders. 
We further attempted to reduce the bias by adjusting for 
comorbid medical status using Charlson Comorbidity Index 
exposure as described below.
Data collection
Health science research personnel extracted data from the 
electronic medical records of patients enrolled in the study. 
The abstractors were blinded to the study hypothesis and were 
not involved with the analysis or interpretation of the data. 
Electronic medical records contained all medical diagnosis and 
demographic information for each patient. The Mayo Clinic 
maintains an electronic system for clinical use, billing, and 
medical archives through the Rochester Epidemiology Project.15 
Using this administrative electronic information, the authors 
collected the demographics, 25-hydroxyvitamin D levels, and 
other comorbid health risk factors for cases and controls. The 
medical provider made the final clinical diagnosis of pressure 
ulcer in the electronic medical records. All 25-hydroxyvitamin D 
levels were drawn and available in medical records at the Mayo 
Clinic. The levels were measured by liquid chromatography-
tandem mass spectrometry. All comorbid conditions were 
identified by ICD-9 codes from administrative/billing data.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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exposure variables
25-hydroxyvitamin D was the primary exposure variable 
of interest. In the clinical laboratory at the Mayo Clinic, 
a deuterated stable isotope (d3-25-hydroxyvitamin D) is 
added to a 0.1 mL serum sample as the internal standard. 
25-hydroxyvitamin D2, 25-hydroxyvitamin D3, and the 
internal standard are extracted with acetone and ethyl acetate. 
The extracts are then derivatized before being analyzed by 
liquid chromatography-tandem mass spectrometry using 
multiple reaction monitoring. 25-hydroxyvitamin D2 and 
25-hydroxyvitamin D3 levels are quantified and reported 
individually and as a sum.
Demographic variables collected included age and gender. 
Comorbid conditions were identified from administrative/
billing data on the day that the 25-hydroxyvitamin D levels 
were obtained. For subjects with multiple 25-hydroxyvitamin 
D levels, the last 25-hydroxyvitamin D level was taken 
into consideration. Patients were dichotomized into 
normal or low vitamin D levels. According to the medical 
laboratories at the Mayo Clinic, 25-hydroxyvitamin D levels 
25–80 ng/mL are considered normal, and levels , 25 ng/mL 
are considered deficient, with ,10 ng/mL being considered 
very deficient16 (see Table 1). Subjects having vitamin 
D levels , 25 ng/mL were labeled as Group 1 and 
25-hydroxyvitamin D levels . 25 ng/mL were considered 
normal and labeled as Group 2.
Comorbid medical conditions were identified and 
given a Charlson Comorbidity Index score. The Charlson 
Comorbidity Index score predicts the 1-year mortality for a 
patient who has comorbid conditions such as heart disease, 
acquired immunodeficiency syndrome, or cancer (a total of 
22 conditions). Each condition is assigned a score of 1, 2, 
3, or 6, depending on the risk of dying associated with the 
condition. The scores are then summed and given a total 
score.17,18 Table 2 describes the scoring system for the Charlson 
Comorbidity Index.
Data analysis and statistical methods
Initial analysis included univariate analysis of 25-hydroxyvi-
tamin D levels and pressure ulcers using conditional logistic 
regression. Charlson Comorbidity Index and vitamin D levels 
were also evaluated using conditional logistic regression. 
The final analysis used multivariate conditional logistic 
regression analysis with both vitamin D levels and Charlson 
Comorbidity Index.
Results
The initial cohort of individuals with 25-hydroxyvitamin D 
levels was 1790 patients within the appointed time frame. Of 
these 1790 individuals, the nested case–control study used 
all 123 patients with identified pressure ulcers (see Figure 1). 
These cases were matched for age within 4 years, except 
for two people. One of the controls matched with an age 
difference within 5 years and the other within 8 years.
Mean age of patients in the control group was 80.31 years 
and in cases was 80.46 years. There was no significant 
  difference between the ages in both groups. The descriptive 
findings between the cases and controls are shown in Table 3. 
Of note in the descriptive statistics, there were statistically 
Table 1 Mayo Clinic medical laboratory reference ranges for 
total serum 25-hydroxyvitamin D15
Severe deficiency ,0 ng/mL
Mild to moderate deficiency 10–24 ng/mL
Optimal 25–80 ng/mL
Possible toxicity .80 ng/mL
By permission of Mayo Foundations for Medical education and research. All rights 
reserved.
Table 2 Weighted Charlson Comorbidity Index17 for comorbidities 
and age
Weight age (years)
  0  0–49
  1  50–59
  2  60–69
  3  70–79
  4  80–89
  5  90–99
Weight clinical condition
Myocardial infarct
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Dementia
Chronic pulmonary disease
Connective tissue disease
Ulcer disease
Mild liver disease
Diabetes
  1  hemiplegia
      Moderate or severe renal disease
      Diabetes with end organ damage
      Any tumor
      Leukemia
      Lymphoma
  2  Moderate or severe liver disease
  6  Metastatic solid tumor
Acquired immunodeficiency syndrome
reprinted from Journal of Chronic Disease, Vol 40, Issue 5, Charlson et al, A new 
method of classifying prognostic comorbidity in longitudinal studies: Development 
and validation, 373–383, Copyright (1987), with permission from elsevier.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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significant differences in the comorbid illnesses of diabetes 
(38% of cases and 20% of controls), congestive heart failure 
(54% of cases and 30% of controls), and renal disease (57% 
of cases and 35% of controls). The average number of days 
of follow-up from the vitamin D draw to pressure ulceration 
or last follow-up was 596.35 ± 681.52 days among cases and 
1043.93 ± 625.44 days among controls.
The mean continuous 25-hydroxyvitamin D level among 
cases was 30.9 ng/mL and among controls was 35.32 ng/mL, 
with a P value of 0.037. The mean Charlson   Comorbidity 
Index score was 10.54 among cases and 8.57 among con-
trols, for a P value of ,0.001. Using dichotomous vita-
min D deficiency or normal, 31% of cases were vitamin 
D-deficient compared with 20% of controls who were vitamin 
D-deficient.
The primary univariate findings are shown in Table 4. 
Vitamin D deficiency was associated with pressure ulcer-
ation (odds ratio [OR]: 1.871, P = 0.0154). The Charlson 
Comorbidity Index score was also associated with pressure 
ulcers (OR: 1.136, P , 0.001). For every unit increase in 
Charlson Comorbidity Index, the risk of pressure ulceration 
increased by 14%.
After initial univariate evaluation, multivariable con-
ditional logistic regression for vitamin D level and comor-
bidities was performed. The association of continuous 
25-hydroxyvitamin D and pressure ulceration became non-
significant after adjustment using the Charlson Comorbidity 
Index. Analyzing the data using dichotomous vitamin D 
deficiency versus normal also found no significant difference 
between pressure ulcer cases and controls in the model. The 
Charlson Comorbidity Index remained a significant predictor 
in the final model (see Table 5).
This was a pilot study to determine the variance 
of   vitamin D levels and pressure ulcers. We found a 
0.11 increased risk of vitamin D deficiency in patients with 
pressure ulcers compared with controls without ulcers. 
There were 123 pressure ulcer cases. Based upon a sample 
size of 123, a power calculation was obtained prior to 
analysis; 123 pairs had 90% power to detect a difference 
in   proportions of 0.190 when the proportion of discordant 
pairs was expected to be 0.450 and the method of analysis 
was a McNemar’s test of equality of paired proportions with 
a 0.050 two-sided significance level. Thus, this initial pilot 
study was underpowered to detect a difference in exposure 
between cases and controls.
Discussion
In this nested case–control study, Vitamin D deficiency was 
not different between pressure ulcer cases and age-matched 
and gender-matched controls after adjusting for comorbid 
medical conditions. In univariate analysis, vitamin D defi-
ciency (levels , 25 ng/mL) was associated with pressure 
ulceration (OR: 1.871, P = 0.0154). The Charlson Comorbid-
ity Index was also associated with pressure ulcers (OR: 1.136, 
P , 0.001). In the multivariate model, when both exposures 
were added, the association between vitamin D deficiency 
Cohort with
vitamin D levels 
1790
Pressure ulcer
cases
123
Controls
246
25-hydroxyvitamin 
D levels
less than 25 ng/mL 
48 
25-hydroxyvitamin D
levels greater than 
25 ng/mL 
198 
25-hydroxyvitamin D
levels less than
25 ng/mL 
38 
25-hydroxyvitamin D 
levels greater 
than 25 ng/mL 
85
Matched
on age ± 4
years and 
gender
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and pressure ulceration became nonsignificant. This finding 
may represent a true lack of association of vitamin D levels 
and development of pressure ulcers. We also noted that this 
pilot study was underpowered to detect a difference between 
the two groups. All identified cases of pressure ulceration 
within the cohort were used for this case–control study. Thus, 
there still may be an association between vitamin D levels 
and pressure ulcers that was not detected by this study. These 
findings are novel and help to improve our understanding 
of pressure ulcers and the role of vitamin D in this disorder, 
despite the negative findings.
Malnutrition has been recognized as a risk factor for the 
onset and perpetuation of pressure sores, hence the interest in 
specific nutritional factors which impact ulcer   development. 
Of the dietary factors, protein intake seems to be the most 
important. A low body mass index, low serum albumin, and 
weight loss are associated with an increased risk of pres-
sure ulcers.19 Given the relationship between malnutrition 
and pressure ulceration, one might think that vitamin D 
deficiency may play a role in pressure ulcer development. 
There are very few studies that have looked into the role of 
specific nutritional deficiencies. Unfortunately, there is no 
evidence in the literature looking specifically at vitamin D 
and pressure ulcers. Our study provides some first steps in the 
understanding of vitamin D and pressure ulceration despite 
the lack of statistical significance of its findings. The impact 
of vitamin D supplementation and pressure ulcer develop-
ment is completely unknown.
Vitamin D deficiency has developed rapidly into a 
problem of considerable proportions in older adults, with 
25%–50% of nursing home or housebound residents, 44% 
of elderly ambulatory women aged .80 years, and 57% of 
hospitalized adult patients (mean age 62 years) being vitamin 
D-deficient.16 During the past decade, major advances have 
been made in vitamin D research with regards to health in 
older adults. Vitamin D deficiency has been associated with 
many illnesses, including osteoporosis, falls,20 and frailty 
in the elderly.21 Importantly, vitamin D supplementation 
has been used in some disorders of the skin. Vitamin D 
  analogs are being used routinely for psoriasis22 and other 
Table 3 Characteristics of cases with pressure ulcers and control subjects
Variable Overall Controls Cases P value
(n = 369) (n = 246) (n = 123)
Age at vitamin D draw date (years) 80.36 ±8.62 80.31 ±8.61 80.46 ±8.67 0.88
Charlson Comorbidity Index
  severity weighted sum of diseases 5.67 ±4.09 5.02 ±3.92 6.97 ±4.13 ,0.001
  severity and age weighted sum of disease 9.23 ±4.19 8.57 ±4.13 10.54 ±4.03 ,0.001
25-hydroxyvitamin D (ng/mL) 33.85 ±19.07 35.32 ±21.51 30.92 ±12.46 0.037
From first vitamin D date to last follow-up (days) 1276.38 ±757.5 1231.72 ±718.57 1365.69 ±825.87 0.11
From vitamin D date to pressure ulcer or  
last follow-up (days)
894.73 ±677.53 1043.93 ±625.44 596.35 ±681.52 ,0.001
From last vitamin D date to last follow-up (days) 1065.40 ±654.62 1043.93 ±625.44 1108.36 ±710.12 0.37
Male gender, n (%) 141 38% 94 38% 47 38% 1
25-hydroxyvitamin D , 25, n (%) 86 23% 48 20% 38 31% 0.015
Myocardial infarction, n (%) 91 25% 51 21% 40 33% 0.013
Congestive heart failure, n (%) 139 38% 73 30% 66 54% ,0.001
Peripheral vascular disease, n (%) 108 29% 63 26% 45 37% 0.029
Cerebrovascular disease, n (%) 173 47% 107 43% 66 54% 0.07
Dementia, n (%) 23 6% 18 7% 5 4% 0.22
Chronic pulmonary disease, n (%) 133 36% 85 35% 48 39% 0.40
Ulcer, n (%) 113 31% 72 29% 41 33% 0.42
Mild liver disease, n (%) 24 7% 12 5% 12 10% 0.07
Diabetes, n (%) 97 26% 50 20% 47 38% ,0.001
Diabetic end organ damage, n (%) 56 15% 26 11% 30 24% ,0.001
hemiplegia, n (%) 25 7% 12 5% 13 11% 0.04
renal failure, n (%) 156 42% 86 35% 70 57% ,0.001
Moderate to severe liver disease, n (%) 9 2% 4 2% 5 4% 0.15
Metastatic disease, n (%) 48 13% 32 13% 16 13% 1
Acquired immune deficiency syndrome, n (%) 0 0% 0 0% 0 0%  
rheumatoid arthritis, n (%) 59 16% 37 15% 22 18% 0.48
Cancer, n (%) 171 46% 107 43% 64 52% 0.12Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Table 4 Univariate analysis
Parameter OR 95% CI P value
Lower Upper
Vitamin D 0.98 0.96 0.98 0.0285
Vitamin D , 25 1.87 1.12 3.10 0.0154
Charlson Comorbidity Index 1.13 1.07 1.20 ,0.0001
Myocardial infarction 1.94 1.16 3.25 0.0115
Congestive heart failure 2.87 1.79 4.62 ,0.0001
Peripheral vascular disease 1.77 1.07 2.90 0.0239
Cerebrovascular disease 1.45 0.95 2.20 0.0798
Dementia 0.54 0.19 1.48 0.2346
Chronic pulmonary disease 1.21 0.77 1.89 0.3994
Ulcer 1.20 0.75 1.92 0.4239
Mild liver disease 2.07 0.90 4.72 0.0832
Diabetes 2.70 1.59 4.60 0.0002
Diabetes with end  
organ damage
3.17 1.65 6.10 0.0005
hemiplegia 2.52 1.05 6.03 0.0368
renal 2.70 1.67 4.39 ,0.0001
Moderate to severe  
liver disease
2.50 0.67 9.31 0.1720
Metastatic 1.00 0.53 1.88 1.0000
rheumatoid arthritis 1.24 0.68 2.24 0.4756
Cancer 1.44 0.91 2.27 0.1107
Abbreviations: CI, confidence interval; OR, odds ratio.
Table 5 Multivariate model
Multivariate model OR P value
Vitamin D 0.985 0.0892
Charlson Comorbidity Index 1.129 ,0.0001
Vitamin D , 25 1.627 0.0730
Charlson Comorbidity Index 1.128 ,0.0001
Abbreviation: Or, odds ratio.
skin disorders. Vitamin D analogs are highly effective agents 
in this disorder.23
Comorbid medical illness measured by the Charlson 
Comorbidity Index was associated with increased risk of pres-
sure ulceration. For every point increase in Charlson Comor-
bidity Index, the risk of pressure ulceration increased by 14%. 
Other investigators have also found a relationship between 
comorbid illness and pressure ulcers. Margolis et al found an 
association between comorbid medical conditions and pressure 
ulcers in older ambulatory patients. They found that conges-
tive heart failure, Alzheimer’s disease, chronic obstructive 
pulmonary disease, cerebrovascular accident, limb paralysis, 
lower limb edema, malignancy, malnutrition, osteoporosis, 
deep venous thrombosis, Parkinson’s disease, rheumatoid 
arthritis, hip fracture, hip surgery, and urinary tract infec-
tions were associated with development of a pressure ulcer.24 
Our findings make sense pathophysiologically. Patients with 
  significant comorbid illnesses are likely to be immobile and 
may suffer from urinary or fecal incontinence which would 
place the patient at further risk for ulceration.
There are limitations to this initial matched case–control 
study. One limitation is the retrospective case–control 
design and data. Administrative data systems suffer inherent 
weaknesses, including potential missing or miscoded 
information. Some of the data challenges are minimized in 
this study because the Mayo Clinic maintains a robust data 
system and comprehensive electronic medical records that 
collect demographic, medical utilization, and comorbidity 
health data. A second concern involves the incident diagnosis 
of pressure ulceration. It is possible that some patients 
developed pressure ulceration and did not seek medical 
attention, so the type of pressure ulcers may have been more 
severe or recalcitrant. This case–control study was drawn 
from a cohort of patients with a pre-existing vitamin D level 
measurement, so it is possible that this cohort may differ 
from a cohort without a vitamin D level drawn. In our study, 
the 25-hydroxyvitamin D levels were drawn considerably 
earlier than the development of pressure ulceration. 
25-hydroxyvitamin D has a serum half-life of 2–3 weeks, 
so the vitamin D level at the time of ulcer development may 
differ from the drawn level. The study was conducted in a 
population of primarily Northern Europeans in a northern US 
state, so the ability to generalize this study beyond Olmsted 
County may be limited. Due to the retrospective nature of 
our study, we did not have information on protein energy 
nutritional status or other nutritional indicators which may 
have acted as confounders. Thus, vitamin D deficiency may 
act as a marker for nutritional deficiency. We did not have 
a standardized pressure ulcer predictor instrument available 
for these ambulatory outpatients, so we used the Charlson 
Comorbidity Index as a means of adjusting for patients at risk 
of pressure ulceration. Lastly, this study was underpowered to 
detect fully a difference after adjustment. It was encouraging 
that the univariate findings did show a difference, and should 
provide some impetus for further work. Despite the study 
limitations, the relationship between vitamin D and pressure 
ulcers needs further explanation and exploration.
Conclusion
Vitamin D deficiency was not associated with pressure 
ulceration in this matched case–control study after adjustment 
for comorbid medical illness. Vitamin D deficiency and 
vitamin D levels were associated with pressure ulcers 
in univariate analysis. Subjects with multiple comorbid 
conditions had an increased risk of pressure ulcers. This was 
a pilot study and was underpowered to detect a difference Clinical Interventions in Aging
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between the groups, so this could explain the lack of 
association. Vitamin D levels may also serve as a surrogate 
for health conditions, with worsening health associated with 
lower vitamin D levels. Despite the negative findings, more 
studies are still needed for better evaluation of the role of 
vitamin D in pressure ulceration. Vitamin D deficiency is 
easy to treat with replacement therapy, hence the importance 
of understanding fully the relationship between the two 
conditions.
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